Heart failure/insufficiency is a major health problem, with an increased mortality rate of 20% 1 year after diagnosis and 53% at 5 years after, according to an observational study. The prevalence increases with age, from approximately 1% for people <55 years of age to> 10% for people over 70 years of age. Although over 50% of patients with heart failure are women, they have a higher survival rate than men.
Content
Heart failure is a clinical syndrome characterized by specific symptoms and signs, caused by structural and/or functional cardiac changes, corroborated either by an increase in the level of natriuretic peptides or by objective evidence of pulmonary or systemic congestion. It is the final stage of all cardiovascular disease when the ability of the heart to pump blood to organs and tissues and to receive blood back from them is affected.
Heart failure is caused by a wide range of heart conditions, the most common being:
The cardinal symptoms of heart failure are:
Diagnosis of heart failureThe diagnosis of heart failure is made in stages. The first stage involves a detailed history of assessing the presence of symptoms of heart failure (eg dyspnea, fatigue) and cardiovascular risk factors (smoking, alcohol consumption, obesity, hypertension, dyslipidemia, diabetes). Subsequently, the physical examination is important for the detection of signs of heart failure (eg peripheral oedema, pulmonary stasis) and is completed with a resting electrocardiogram to check for changes in cardiac electrical activity. Usual laboratory tests are also needed to evaluate other comorbidities. Pulmonary radiography is useful to identify other possible causes of dyspnea (eg lung disease) but also to provide evidence of heart failure (eg pulmonary congestion, cardiomegaly - enlarged heart)
The second stage involves the collection of natriuretic peptides (most often NT-proBNP), substances secreted by overloaded cardiac myocytes.
In the third stage, if the natriuretic peptides show high concentrations, it is necessary to perform echocardiography to assess the presence of structural and/or functional changes but also to establish the type of heart failure: with preserved left ventricular ejection fraction (≥50%), moderate-low (41-49%) or low (≤40%).
In the last stage, paraclinical investigations will be performed to elucidate the cause of heart failure, depending on the context of each patient, such as Holter ECG / 24h, exercise ECG test, coronary angioCT, coronary angiography, myocardial scintigraphy, cardiac MRI, etc.
The treatment of heart failure is varied. Lifestyle modification is essential for proper control of heart failure by :reducing salt intake (<5g / day), reducing fluid intake to 1.5-2l / day in severe forms and regular monitoring of body weight (an increase in > 2kg in 3 days suggesting fluid retention), optimal control of cardiovascular risk factors (eg smoking /alcohol consumption, weight loss, monitoring of blood pressure at home, periodic monitoring of lipid and glycemic profile in patients diabetics).
Pharmacological treatment involves multiple classes of drugs that aim to improve symptoms, improve heart function and reduce mortality.
It must be individualized in each patient by a cardiologist, according to the European guidelines in force, depending on the type of heart failure and the associated comorbidities.
In some cases the pharmacological treatment is not enough, it is necessary to resort to an interventional/surgical treatment that involves: implantation of special devices (cardiac resynchronization therapy, implantable defibrillator), coronary revascularization by implanting a stent or performing an aortocoronary bypass, replacing a dysfunctional valve.
Despite maximal therapy, heart failure may progress to advanced stages, with indications for ventricular assist devices, as a bridge either to the recovery of heart function, or to a heart transplant, or as a final destination in patients ineligible for heart transplantation.
The article was written by Dr. Ionela - Simona Visoiu, Cardiology specialist